Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid.
about
Trials with 'epigenetic' drugs: an updateValproic acid for the treatment of low-risk myelodysplastic syndromes: A case report and a review of the literature.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?New perspectives of valproic acid in clinical practice.Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cellsEfficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemiaParameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.Deacetylase inhibitors for the treatment of myelodysplastic syndromes.Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses.EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia.Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).Megakaryocyte lineage development is controlled by modulation of protein acetylation.Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.
P2860
Q27000542-DBC861DD-51AD-4B8A-ABDB-D44D4E1830FAQ33412339-E5137F03-F5D2-41AC-839A-291EBA0C6854Q34342944-887183E0-EF25-4BB9-A99E-1577448D8D31Q34380256-086746F5-B8FF-4A42-9BAB-64F69C3A6467Q35677279-91AFFD54-8B08-4AE8-86BC-6FCE8B944390Q35742564-80ECD639-341C-45F1-8D25-3A64CE8C8581Q36579081-5229C6EF-773D-4113-95CA-8A5D542E4A60Q38160051-AD57DCB9-670D-4C61-A68A-EA0E0CD63717Q38233492-C8E08691-28B7-4DDE-B0DE-F3E6EA652A98Q38242979-1E3FB46B-930C-430C-8D70-FC3C38F196F9Q38572855-0D000E83-F1E2-4364-89BB-6FBE3FDA6CDFQ38753922-1C8869C1-DA9A-4E87-B819-BA4482598E14Q39160149-DE7745A4-1121-4EBB-8A03-B2EA8D64F74CQ40420210-5BF8A0E8-8A40-4AB7-A02A-45B3A590F0A3Q41915700-FBDA1543-9CE5-4745-8F91-C4C685123A80Q48198254-B0F6E238-4AC1-4DB2-843D-78CAD59BCFF0Q52716487-07CC5422-978D-455E-8BBB-C1DB70B006DAQ55364989-70649354-B491-49EB-B72D-AA0D8EFE4F0B
P2860
Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Treatment of poor-risk myelody ...... azacytidine and valproic acid.
@ast
Treatment of poor-risk myelody ...... azacytidine and valproic acid.
@en
type
label
Treatment of poor-risk myelody ...... azacytidine and valproic acid.
@ast
Treatment of poor-risk myelody ...... azacytidine and valproic acid.
@en
prefLabel
Treatment of poor-risk myelody ...... azacytidine and valproic acid.
@ast
Treatment of poor-risk myelody ...... azacytidine and valproic acid.
@en
P2093
P2860
P50
P1433
P1476
Treatment of poor-risk myelody ...... azacytidine and valproic acid.
@en
P2093
Andrea Kuendgen
Ariane Dienst
Barbara Hildebrandt
Detlef Haase
Gesine Bug
Judith Neukirchen
Julie Schanz
Oliver G Ottmann
Rainer Haas
P2860
P2888
P304
P356
10.1007/S13148-011-0031-9
P577
2011-04-08T00:00:00Z
P5875
P6179
1034458391